Preclinical Evaluation of EC145, a Folate-Vinca Alkaloid Conjugate
- 1 May 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (9), 4434-4442
- https://doi.org/10.1158/0008-5472.can-07-0033
Abstract
We recently developed a new group of folate-conjugated Vinca alkaloids, one of which, EC145, emerged as a candidate for clinical development. Brief treatment of nude mice bearing ∼100 mm3 folate receptor-positive human xenografts led to complete response (CR) in 5/5 mice and cures (i.e., remission without a relapse for >90 days post-tumor implantation) in 4/5 mice. Multiple CRs and cures were also noted when EC145 was used to treat mice initially bearing tumors as large as 750 mm3. Likewise, complete cures (5/5) resulted following the treatment of an aggressive folate receptor–positive J6456 lymphoma model. The activity of EC145 was not accompanied by noticeable weight loss or major organ tissue degeneration. Furthermore, no significant antitumor activity (0/5 CR) was observed in EC145-treated animals that were co-dosed with an excess of a benign folate ligand, thus demonstrating the target-specific activity of EC145. The enhanced therapeutic index due to folate conjugation was also evidenced by the fact that the unconjugated drug (desacetylvinblastine monohydrazide) was found to be completely inactive when administered at nontoxic dose levels and only marginally active when given at highly toxic dose levels. Subsequent dose regimen studies confirmed that EC145 given on a more frequent, qdx5 schedule resulted in the most effective antitumor response as compared with an equivalent total dose given on thrice- or single-injection-per-week schedule. Taken together, these studies show that EC145 has significant antiproliferative activity and tolerability, thus lending support to an ongoing phase 1 trial for the treatment of advanced malignancies. [Cancer Res 2007;67(9):4434–42]Keywords
This publication has 22 references indexed in Scilit:
- A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinomaLung Cancer, 2006
- Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazideBioorganic & Medicinal Chemistry Letters, 2006
- Folate-Mediated Delivery of Protein and Peptide Drugs into TumorsPublished by World Scientific Pub Co Pte Ltd ,2006
- Antibody targeted drugs as cancer therapeuticsNature Reviews Drug Discovery, 2006
- Synthesis and Biological Evaluation of EC72: A New Folate-Targeted ChemotherapeuticBioconjugate Chemistry, 2005
- Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assayAnalytical Biochemistry, 2005
- Folate receptor-targeted drugs for cancer and inflammatory diseasesAdvanced Drug Delivery Reviews, 2004
- Gemtuzumab ozogamicin in the treatment of acute myeloid leukemiaCancer, 2003
- Antibody-targeted chemotherapy with immunoconjugates of calicheamicinCurrent Opinion in Pharmacology, 2003
- Folate-targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumorsGene Therapy, 2002